| Identification | Back Directory | [Name]
TAS-115 Methanesulfonic acid salt | [CAS]
1688673-09-7 | [Synonyms]
TAS115;TAS 115
TAS-115 mesylate
Pamufetinib (mesylate)
TAS-115 methanesulfonate
TAS-115 Methanesulfonic acid salt
TAS-115 mesylate (TAS-115 methanesulfonate)
TAS-115 mesylate (Synonyms: TAS-115 methanesulfonate) | [Molecular Formula]
C28H27FN4O7S2 | [MDL Number]
MFCD31807633 | [MOL File]
1688673-09-7.mol | [Molecular Weight]
614.66 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: slightly soluble; PBS (pH 7.2): slightly soluble; Water: slightly soluble | [form ]
A crystalline solid | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Pamufetinib (TAS-115) mesylate is a potent VEGFRand hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase inhibitor, with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively. | [in vivo]
Pamufetinib mesylate completely suppresses the progression of MET-inactivated tumor by blocking angiogenesis without toxicity when given every day for 6 weeks, even at a serum-saturating dose of Pamufetinib mesylate. Pamufetinib mesylate induces marked tumor shrinkage and prolonges survival in MET-amplified human cancer–bearing mice[1]. | [storage]
Store at -20°C | [References]
[1] Fujita H, et al. The novel VEGF receptor/MET-targeted kinase inhibitor TAS-115 has marked in vivo antitumor properties and a favorable tolerability profile. Mol Cancer Ther. 2013 Dec;12(12):2685-96. DOI:10.1158/1535-7163.MCT-13-0459
[2] Nakade J, et al. Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation. J Thorac Oncol. 2014 Jun;9(6):775-83. DOI:10.1097/JTO.0000000000000170 |
|
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
| Company Name: |
ABBIOCHEM
|
| Tel: |
18964309092 |
| Website: |
http://www.abbiochemical.com |
|